Quarterly report pursuant to Section 13 or 15(d)

Condensed Statement of Changes in Stockholders??? Equity (Deficit) (Unaudited)

v3.23.2
Condensed Statement of Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   7,809,912    
Beginning balance at Dec. 31, 2021 $ 13,410 $ 1 $ 22,633 $ (9,224)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 423   423  
Sale of Common Stock and Warrants (in shares)   136,025    
Sale of Common Stock, net of issuance costs 804   804  
Stock issuance upon vesting and exercise of stock options (in shares)   28,571    
Stock issuance upon vesting and exercise of stock options 2   2  
Stock issuance upon vesting of restricted stock awards (in shares)   7,500    
Net loss (5,671)     (5,671)
Ending balance (in shares) at Jun. 30, 2022   7,982,008    
Ending balance at Jun. 30, 2022 8,968 $ 1 23,862 (14,895)
Beginning balance (in shares) at Mar. 31, 2022   7,958,888    
Beginning balance at Mar. 31, 2022 12,227 $ 1 23,596 (11,370)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 264   264  
Stock issuance upon vesting and exercise of stock options (in shares)   19,370    
Stock issuance upon vesting and exercise of stock options 2   2  
Stock issuance upon vesting of restricted stock awards (in shares)   3,750    
Net loss (3,525)     (3,525)
Ending balance (in shares) at Jun. 30, 2022   7,982,008    
Ending balance at Jun. 30, 2022 8,968 $ 1 23,862 (14,895)
Beginning balance (in shares) at Dec. 31, 2022   8,009,743    
Beginning balance at Dec. 31, 2022 2,374 $ 1 24,559 (22,186)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 1,095   1,095  
Sale of Common Stock and Warrants (in shares)   17,872,955    
Sale of Common Stock, net of issuance costs $ 24,764 $ 2 24,762  
Stock issuance upon vesting and exercise of stock options (in shares) 88,026 88,026    
Stock issuance upon vesting and exercise of stock options $ 103   103  
Stock issuance upon vesting of restricted stock awards (in shares)   12,500    
Stock issuance upon exercise of warrants (in shares) 1,471 7,292    
Stock issuance upon exercise of warrants $ 16   16  
Net loss (7,290)     (7,290)
Ending balance (in shares) at Jun. 30, 2023   25,990,516    
Ending balance at Jun. 30, 2023 21,062 $ 3 50,535 (29,476)
Beginning balance (in shares) at Mar. 31, 2023   8,227,074    
Beginning balance at Mar. 31, 2023 (859) $ 1 25,462 (26,322)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock based compensation expense 702   702  
Sale of Common Stock and Warrants (in shares)   17,666,666    
Sale of Common Stock, net of issuance costs 24,270 $ 2 24,268  
Stock issuance upon vesting and exercise of stock options (in shares)   88,026    
Stock issuance upon vesting and exercise of stock options 103   103  
Stock issuance upon vesting of restricted stock awards (in shares)   8,750    
Net loss (3,154)     (3,154)
Ending balance (in shares) at Jun. 30, 2023   25,990,516    
Ending balance at Jun. 30, 2023 $ 21,062 $ 3 $ 50,535 $ (29,476)